
Sign up to save your podcasts
Or


Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150
Landing Page: https://ebrheum.com/
Substack: https://autoimmunedevreport.substack.com/
By Michael Putman4.9
114114 ratings
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150
Landing Page: https://ebrheum.com/
Substack: https://autoimmunedevreport.substack.com/

506 Listeners

299 Listeners

124 Listeners

3,360 Listeners

1,152 Listeners

120 Listeners

197 Listeners

517 Listeners

68 Listeners

4 Listeners

373 Listeners

182 Listeners

188 Listeners

17 Listeners

6 Listeners